| bortezomib / Generic mfg. |
NCT00051987: Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma |
|
|
| Completed | 2b | 175 | US | VELCADE TM (bortezomib) for Injection, or PS-341 | Millennium Pharmaceuticals, Inc. | Colorectal Carcinoma | 03/04 | | | |
NCT01237249 / 2010-018379-70: Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone |
|
|
| Completed | 2b | 250 | Europe | Melphalan, Prednisone, Velcade, Revlimid, Dexamethasone | PETHEMA Foundation, Janssen-Cilag Ltd., Celgene, TFS Trial Form Support | Multiple Myeloma | 08/14 | 05/16 | | |
|
| Completed | 2b | 202 | Europe, US | Selinexor, KPT-330, Dexamethasone | Karyopharm Therapeutics Inc | Multiple Myeloma | 07/19 | 07/19 | | |
|
|
|
|
|
NCT01009840: IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients |
|
|
| Completed | 2a | 30 | US, Canada | IV busulfan, Busulfex®, bortezomib, Velcade®, Autologous Hematopoietic Stem Cell Transplant (HSCT) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Multiple Myeloma | 03/12 | 03/12 | | |
| Completed | 2a | 34 | Europe | BORTEZOMIB | Assistance Publique - Hôpitaux de Paris | Waldenstrom Macroglobulinemia | 08/12 | 08/12 | | |
| Completed | 2a | 28 | Europe | NOX-A12, olaptesed | TME Pharma AG | Multiple Myeloma | 09/14 | 09/15 | | |
CMRG 006, NCT04258683: A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE |
|
|
| Withdrawn | 2a | 0 | Canada | Pembrolizumab, Keytruda | Canadian Myeloma Research Group, Merck Sharp & Dohme LLC | Multiple Myeloma | 10/22 | 10/22 | | |
ACTRN12616001187437: Molecular Profiling and Matched Targeted Therapy for Patients with Metastatic Melanoma (MatchMel) |
|
|
| Not yet recruiting | 2 | 1000 | | | Melanoma Institute Australia, Melanoma Institute Australia, National Health and Medical Research Council | Metastatic Melanoma | | | | |
ACTRN12611000605998: A Phase II trial of bortezomib and dexamethasone in
renally-impaired patients with untreated multiple myeloma. |
|
|
| Recruiting | 2 | 28 | | | Prof. Andrew Spencer, Janssen-Cilag Pty Ltd | Untreated Multiple Myeloma patients with renal impairment. | | | | |
ACTRN12605000770662: A pilot study to explore the tolerability and efficacy of bortezomib as part of induction and post-transplant therapy in multiple myeloma |
|
|
| Completed | 2 | 60 | | | Clinical Haematology & Bone Marrow Transplant Unit, Royal Adelaide Hospital, Janssen-Cilag Pty Limited | Multiple myeloma | | | | |
ACTRN12606000180516: Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse |
|
|
| Completed | 2 | 100 | | | Peter MacCallum Cancer Centre, Janssen-Cilag | Multiple Myeloma | | | | |
ACTRN12622001366741: Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial |
|
|
| Recruiting | 2 | 120 | | | Australasian Myeloma Research Consortium, Australasian Myeloma Research Consortium | Multiple Myeloma | | | | |
NCT00025376: PS-341 in Treating Patients With Metastatic Kidney Cancer |
|
|
| Completed | 2 | 23 | US | PS-341, Tumor Biopsy | University of Chicago, National Cancer Institute (NCI) | Kidney Cancer | 09/02 | 03/06 | | |
NCT00066352: Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter |
|
|
| Completed | 2 | | US, Canada | bortezomib | University Health Network, Toronto, National Cancer Institute (NCI) | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | 09/03 | | | |
NCT00028639: PS-341 in Treating Women With Metastatic Breast Cancer |
|
|
| Completed | 2 | | US | bortezomib | Northwestern University, National Cancer Institute (NCI) | Breast Cancer | 11/03 | 11/03 | | |
NCT00017329: PS-341 in Treating Patients With Metastatic Kidney Cancer |
|
|
| Completed | 2 | | US | bortezomib | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Kidney Cancer | 04/04 | | | |
NCT00027716: Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma |
|
|
| Completed | 2 | | US | bortezomib | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Sarcoma | 05/04 | 05/04 | | |
NCT00064012: Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 4 | US | bortezomib, docetaxel | University of Wisconsin, Madison, National Cancer Institute (NCI) | Lung Cancer | 07/04 | 07/04 | | |
NCT00025584: PS-341 in Treating Women With Metastatic Breast Cancer |
|
|
| Completed | 2 | 35 | US | bortezomib, LDP 341, MLN341, VELCADE, laboratory biomarker analysis | National Cancer Institute (NCI) | Recurrent Breast Cancer, Stage IV Breast Cancer | 08/04 | | | |
NCT00051974: Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 155 | US | VELCADE™ (bortezomib) for Injection (formerly PS-341) | Millennium Pharmaceuticals, Inc. | Non-Small Cell Lung Cancer | 09/04 | | | |
NCT00023881: Bortezomib in Treating Patients With Chronic Myelogenous Leukemia |
|
|
| Terminated | 2 | 7 | US | bortezomib | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Leukemia | 03/05 | 03/05 | | |
NCT00038571: Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy |
|
|
| Completed | 2 | 60 | US | PS341 (Bortezomib), Velcade, LPD-341, MLN341, PS-341 | M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc. | Lymphoma, B-Cell | 03/05 | 03/05 | | |
NCT00074009: Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma |
|
|
| Completed | 2 | | US | bortezomib | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Gastric Cancer | 04/05 | | | |
NCT00066508: Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy |
|
|
| Completed | 2 | 7 | US | bortezomib | Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI) | Lymphoma | 07/05 | | | |
NCT00030875: Bortezomib in Treating Patients With Mantle Cell Lymphoma |
|
|
| Completed | 2 | 30 | Canada | bortezomib | NCIC Clinical Trials Group | Lymphoma | 07/05 | 12/09 | | |
NCT00052507: Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer |
|
|
| Completed | 2 | | Canada | bortezomib | University Health Network, Toronto, National Cancer Institute (NCI) | Colorectal Cancer | 08/05 | | | |
NCT00093769: Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma |
|
|
| Completed | 2 | 15 | US | bortezomib + rituximab | Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI) | Lymphoma | 08/05 | | | |
NCT00103103: Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer |
|
|
| Terminated | 2 | | US | bortezomib, fluorouracil, leucovorin calcium | California Cancer Consortium, National Cancer Institute (NCI) | Gastric Cancer | 08/05 | 08/05 | | |
NCT00087867: Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma |
|
|
| Completed | 2 | 62 | US | SCIO-469, SCIO-469 and bortezomib | Scios, Inc. | Multiple Myeloma | | 09/05 | | |
NCT00193232: Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer |
|
|
| Completed | 2 | 50 | US | Docetaxel, Bortezomib | SCRI Development Innovations, LLC, Aventis Pharmaceuticals, Millennium Pharmaceuticals, Inc. | Prostate Cancer | 10/05 | 02/07 | | |
NCT00063713: VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma |
|
|
| Completed | 2 | 152 | US | VELCADE TM (bortezomib) for Injection | Millennium Pharmaceuticals, Inc. | Mantle Cell Lymphoma | 12/05 | | | |
NCT00169468: Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma |
|
|
| Completed | 2 | 48 | Europe | Rituximab -CHOP plus Velcade | Lymphoma Study Association, Association pour le Développement de la Recherche Clinique et Informatique en Onco-Hématologie | B Cell Lymphoma | 01/06 | 01/06 | | |
NCT00095680: Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma |
|
|
| Completed | 2 | 30 | US | SCIO-469, SCIO-469 and bortezomib | Scios, Inc. | Multiple Myeloma | | 02/06 | | |
NCT00040768: Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer |
|
|
| Terminated | 2 | 35 | US | bortezomib, LDP 341, MLN341, VELCADE | National Cancer Institute (NCI) | Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | 03/06 | | | |
NCT00045695: Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia |
|
|
| Completed | 2 | 27 | US, Canada | bortezomib | NCIC Clinical Trials Group, National Cancer Institute (NCI), Eastern Cooperative Oncology Group | Lymphoma | 03/06 | 12/09 | | |
NCT00072150: Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma |
|
|
| Completed | 2 | 40 | US | bortezomib, LDP 341, MLN341, VELCADE | National Cancer Institute (NCI) | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer | 03/06 | | | |
2005-005794-29: Traitement des syndromes myélodysplasiques par l'association aracytine et bortezomib |
|
|
| Ongoing | 2 | 39 | Europe | Aracytine, velcade, Powder and solvent for solution for injection, Cytosar, velcade | Groupe français des Myélodysplasies | Myelodysplastic syndrome (MDS) is a clonal disease of the bone marrow stem cells. The disease is frequently associated with cytopenia and/or blastosis. An evolution to an acute leukemia is not unfrequent (~ 30%). Treatments are very disapointing especially for high risk MDS. The prognosis mainly depends on blastosis, cytopenia and cytogenetic abnormalities but the disease is typically uncurable (except BMT). | | | | |
NCT00085696: VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma |
|
|
| Completed | 2 | 66 | US | VELCADE and rituximab | Millennium Pharmaceuticals, Inc. | B-Cell Lymphoma, Follicular Lymphoma, Marginal Lymphoma | 04/06 | | | |
NCT00193557: Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma |
|
|
| Completed | 2 | 40 | US | Bortezomib | SCRI Development Innovations, LLC, Millennium Pharmaceuticals, Inc. | Multiple Myeloma | 05/06 | 01/09 | | |
NCT00077441: Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) |
|
|
| Completed | 2 | 55 | US | bortezomib, LDP 341, MLN341, VELCADE, laboratory biomarker analysis | National Cancer Institute (NCI) | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer | 06/06 | | | |
NCT00337506: Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma |
|
|
| Terminated | 2 | 50 | Europe | Dexamethasone, velcade | Nantes University Hospital | Multiple Myeloma | | | | |
NCT00512798: Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma |
|
|
| Terminated | 2 | 47 | US | PS-341 (VELCADE), bortezomib, temozolomide, TMZ, immunoenzyme technique, None noted, Temozolomide | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors, Melanoma, Solid Tumor | 07/06 | 03/08 | | |
NCT00024011: PS-341 in Treating Patients With Metastatic Malignant Melanoma |
|
|
| Completed | 2 | 50 | US | bortezomib, LDP 341, MLN341, VELCADE, laboratory biomarker analysis | National Cancer Institute (NCI) | Recurrent Melanoma, Stage IV Melanoma | 09/06 | | | |
NCT00216697: An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy |
|
|
| Completed | 2 | 13 | Japan | bortezomib | Janssen Pharmaceutical K.K. | Multiple Myeloma | | 10/06 | | |
NCT00088855: Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma |
|
|
| Completed | 2 | 55 | US | Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, DOX-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, doxorubicin hydrochloride liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, liposomal doxorubicin hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99 | National Cancer Institute (NCI) | DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma | 10/06 | 01/08 | | |
| Unknown status | 2 | 16 | Europe | bortezomib, rituximab, dexamethasone, treatment protocol | Medical University of Vienna | Lymphoma, Mantle-Cell | | 01/07 | | |
| Completed | 2 | 40 | US | Velcade, Doxil, Dexamethasone | University of Michigan Rogel Cancer Center | Multiple Myeloma | 01/07 | 12/07 | | |
NCT00107341: Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction |
|
|
| Completed | 2 | 37 | US | bortezomib, carboplatin, paclitaxel | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Esophageal Cancer | 02/07 | 05/08 | | |
2006-004144-23: Clinical Trial Application for a Phase II study in patients with hormone receptor positive breast cancer with bortezomib (Velcade) in the reversal of endocrine resistance. |
|
|
| Ongoing | 2 | 14 | Europe | Powder for solution for injection, Velcade | AZ St Augustinus, Wilrijk | breast cancer | | | | |
| Ongoing | 2 | 90 | Europe | Velcade | Plymouth Hospitals NHS Trust | Relapsed, or refractory mantle cell lymphoma, Relapsed or refractory mantle cell lymphoma, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT00082966: Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma |
|
|
| Completed | 2 | 43 | US | 17-N-allylamino-17-demethoxygeldanamycin/bortezomib | National Cancer Institute (NCI) | Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma | 03/07 | | | |
NCT00106262: Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer |
|
|
| Terminated | 2 | 38 | US | Velcade (bortezomib), Irinotecan | Women and Infants Hospital of Rhode Island, Millennium Pharmaceuticals, Inc. | Cervical Cancer | | 03/07 | | |
NCT00250926: Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia |
|
|
| Completed | 2 | 23 | US | Bortezomib, Bortezomib (Velcade), Dexamethasone, Dexamethasone (Decadron), Rituximab, Rituximab (Rituxan) | Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Millennium Pharmaceuticals, Inc. | Waldenstrom's Macroglobulinemia | 03/07 | 02/09 | | |
NCT00118183: Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 62 | US | docetaxel, RP 56976, Taxotere, TXT, cetuximab, C225, C225 monoclonal antibody, IMC-C225, MOAB C225, monoclonal antibody C225, bortezomib, LDP 341, MLN341, VELCADE | National Cancer Institute (NCI) | Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | 04/07 | | | |
NCT00017199: PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors |
|
|
| Completed | 2 | | US | bortezomib | Ohio State University Comprehensive Cancer Center, National Cancer Institute (NCI) | Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | | 05/07 | | |
NCT00200382: Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer |
|
|
| Terminated | 2 | 27 | US | PS-341 (Velcade-drug) | Rasim Gucalp, Millennium Pharmaceuticals, Inc. | Non-small Cell Lung Cancer | 05/07 | 05/07 | | |
NCT00561743: A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients |
|
|
| Completed | 2 | 50 | US | Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone | Janssen-Ortho Inc., Canada | Multiple Myeloma | 05/07 | 05/07 | | |
NCT00346645: A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer |
|
|
| Terminated | 2 | 46 | Europe | Bortezomid (VELCADE®) | Gustave Roussy, Cancer Campus, Grand Paris | STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER | 05/07 | 12/07 | | |
NCT00142129: Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia |
|
|
| Completed | 2 | 27 | US | Bortezomib (Velcade) | Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Millennium Pharmaceuticals, Inc. | Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma | 06/07 | 06/07 | | |
NCT00077428: Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck |
|
|
| Completed | 2 | 37 | US | bortezomib, LDP 341, MLN341, VELCADE, doxorubicin hydrochloride, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, laboratory biomarker analysis | National Cancer Institute (NCI), Southwest Oncology Group | Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Adenoid Cystic Carcinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer | 06/07 | | | |
NCT00117351 / 2004-004648-29: VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features |
|
|
| Terminated | 2 | | US | VELCADE | Millennium Pharmaceuticals, Inc. | Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Bronchiolo-Alveolar | 06/07 | 07/07 | | |
NCT00217503: Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma |
|
|
| Completed | 2 | 15 | US | bevacizumab, filgrastim, pegfilgrastim, bortezomib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ganciclovir, valganciclovir, zidovudine | National Cancer Institute (NCI) | Lymphoma | | 06/07 | | |
| Completed | 2 | 40 | Europe | Velcade/Dexamethasone | PETHEMA Foundation | Multiple Myeloma | 06/07 | 01/08 | | |
NCT00431340: A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma |
|
|
| Terminated | 2 | 4 | US | PXD101 | Onxeo | Multiple Myeloma | 06/07 | 06/07 | | |
NCT00068289: Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy |
|
|
| Completed | 2 | | US, Canada | bortezomib | Southwest Oncology Group, National Cancer Institute (NCI) | Lung Cancer | | 07/07 | | |
NCT00153920: Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma |
|
|
| Completed | 2 | 66 | US | bortezomib, Velcade | Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Women's Hospital, Roswell Park Cancer Institute, Emory University, Memorial Sloan Kettering Cancer Center, Millennium Pharmaceuticals, Inc. | Multiple Myeloma | 07/07 | 09/08 | | |
NCT00075751: Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 99 | US | gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, bortezomib, LDP 341, MLN341, VELCADE | National Cancer Institute (NCI) | Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | 07/07 | | | |
NCT00283634: A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer |
|
|
| Terminated | 2 | | US | erlotinib and bortezomib | Millennium Pharmaceuticals, Inc., Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | NSCLC | 07/07 | 08/07 | | |
NCT00305734: Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer |
|
|
| Completed | 2 | 50 | US | bortezomib, LDP 341, MLN341, VELCADE, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, laboratory biomarker analysis | National Cancer Institute (NCI) | Recurrent Nasopharyngeal Cancer, Stage IV Nasopharyngeal Cancer | 07/07 | | | |
NCT00504634: Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma |
|
|
| Completed | 2 | 8 | US | Bortezomib, Velcade, PS-341 | M.D. Anderson Cancer Center | Multiple Myeloma | 08/07 | 05/10 | | |
NCT01902862 / 2005-003949-14: An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma |
|
|
| Terminated | 2 | 7 | Europe | Bortezomib, VELCADE, Rituximab | Janssen-Cilag G.m.b.H | Lymphoma, Follicular | 08/07 | 08/07 | | |
NCT00288041: Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma |
|
|
| Completed | 2 | 36 | US | carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, paclitaxel, Anzatax, Asotax, TAX, Taxol, bortezomib, LDP 341, MLN341, VELCADE | National Cancer Institute (NCI) | Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma | 09/07 | | | |
NCT00343720: Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy |
|
|
| Completed | 2 | | Europe | VELCADE, Alimta | Millennium Pharmaceuticals, Inc., Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Non-Small Cell Lung Cancer | 10/07 | | | |
NCT00052689: Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer |
|
|
| Completed | 2 | 88 | US | bortezomib, gemcitabine hydrochloride | National Cancer Institute (NCI) | Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer | 10/07 | | | |
NCT00210392: VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy |
|
|
| Terminated | 2 | 12 | Europe | Bortezomib (drug) | International Extranodal Lymphoma Study Group (IELSG) | Lymphoma, Mucosa-Associated Lymphoid Tissue | 11/07 | 11/07 | | |
| Terminated | 2 | 3 | US | bortezomib, Velcade, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Radiation therapy | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Millennium Pharmaceuticals, Inc. | Non-Hodgkin's Lymphoma | 11/07 | 05/08 | | |
| Completed | 2 | 48 | Europe | Rituximab, VELCADE | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie, Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte, Fondazione Italiana Linfomi ONLUS, University of Turin, Italy | Lymphoma, Non-Hodgkin Lymphoma | 11/07 | 01/11 | | |
NCT00441168 / 2006-001709-27: Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma |
|
|
| Terminated | 2 | 30 | Europe, RoW | adriamycin, bortezomib, dexamethasone, vincristine | Janssen-Cilag International NV | Multiple Myeloma | 01/08 | 01/08 | | |
NCT00006184: Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma |
|
|
| Completed | 2 | 20 | US | Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Velcade, PS341, Cyclophosphamide, Cytoxan, CTX, Cyclosporine, Sandimmune, Cyclosporin A, Doxorubicin hydrochloride, Etoposide, Vepesid, Fludarabine phosphate, Fludara, Prednisone, Deltasone, Vincristine Sulfate, Methotrexate, MTX, Methotrexate sodium, GMCSF (granulocyte macrophage colony stimulating factor), GCSF (granulocyte colony stimulating factor), Filgrastim, Neupogen | National Cancer Institute (NCI) | Multiple Myeloma | 01/08 | 01/08 | | |
NCT00265928: Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma |
|
|
| Terminated | 2 | 46 | US | bortezomib, rituximab, antibody therapy, biological therapy, enzyme inhibitor therapy, monoclonal antibody therapy | University of Virginia, National Cancer Institute (NCI) | Lymphoma | | | | |
NCT00734149: Bortezomib With Melphalan and Prednisone for Multiple Myeloma |
|
|
| Completed | 2 | 45 | US | Bortezomib, Velcade, Melphalan, Prednisone | Duke University | Multiple Myeloma | 02/08 | 02/08 | | |
NCT00320476: VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates |
|
|
| Completed | 2 | 35 | RoW | Velcade | Korean Multiple Myeloma Working Party, Janssen-Cilag Ltd. | Multiple Myeloma | 02/08 | 02/08 | | |
NCT00128921: Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Terminated | 2 | 18 | US | VELCADE™, Bortezomib | University of Arkansas | Multiple Myeloma | 02/08 | 02/08 | | |
| Completed | 2 | 3 | Europe | Bortezomib | University of Bologna | Leukemia | 02/08 | 02/08 | | |
NCT00440076: Velcade in Myelodysplastic Syndrome - Pilot Study |
|
|
| Terminated | 2 | 28 | Europe | Velcade | Gruppo Italiano Malattie EMatologiche dell'Adulto | MDS | | 03/08 | | |
| Completed | 2 | 13 | Europe | Ifosfamide, Gemcitabine, Vinorelbine, Bortezomib + IGEV | Istituto Clinico Humanitas | Hodgkin Disease | 04/08 | 02/10 | | |
NCT00262860: Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma |
|
|
| Completed | 2 | 18 | US | bortezomib, gemcitabine hydrochloride | University of Rochester | Lymphoma | 05/08 | | | |
NCT00124579: S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Terminated | 2 | 7 | US | bortezomib, dexamethasone, thalidomide | Southwest Oncology Group, National Cancer Institute (NCI) | Multiple Myeloma | 06/08 | 06/10 | | |
NCT00381940: Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy |
|
|
| Completed | 2 | 26 | US | ifosfamide, Cyfos, Holoxan, IFF, IFX, IPP, bortezomib, LDP 341, MLN341, VELCADE, vinorelbine tartrate, Eunades, navelbine ditartrate, NVB, VNB, filgrastim, G-CSF, Neupogen | National Cancer Institute (NCI) | Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Lymphocyte Predominant Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma | 06/08 | 12/16 | | |
NCT00378755: Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM |
|
|
| Unknown status | 2 | 62 | RoW | velcade | Korean Multiple Myeloma Working Party, Janssen-Cilag Ltd. | Multiple Myeloma | | 07/08 | | |
|
NCT00148018: Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma |
|
|
| Terminated | 2 | 37 | Europe | Bortezomib, Dexamethasone | University of Cologne, German Hodgkin's Lymphoma Study Group, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Hodgkin Disease | | | | |
NCT00085410: Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder |
|
|
| Terminated | 2 | 20 | US | bortezomib | National Cancer Institute (NCI) | Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer | 08/08 | 04/10 | | |
| Completed | 2 | 45 | Europe | Bortezomib (VELCADE), VELCADE, Rituximab, Mabthera | Gruppo Italiano Studio Linfomi | Non Hodgkin's Follicular Lymphoma | 08/08 | 05/11 | | |
NCT00054665: PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma |
|
|
| Completed | 2 | 50 | US | PS-341, Velcade, Bortezomib, LDB-341, MLN-341, Etoposide, Vepesid, VP-16, Doxorubicin, Adriamycin, Vincristine, Oncovin, Cyclophosphamide, Cytoxan, Prednisone, Deltasone, Filgrastim, Neupogen | National Cancer Institute (NCI) | B-Cell Lymphoma | 09/08 | 07/09 | | |
NCT00408928: Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease |
|
|
| Completed | 2 | 11 | US | Bortezomib, VELCADE, PS-341 | Sidney Kimmel Cancer Center at Thomas Jefferson University | Graft-versus-Host Disease | 09/08 | 09/09 | | |
NCT00319865: PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma |
|
|
| Unknown status | 2 | 47 | RoW | Velcade, Thalidomide, Adriamycin, Dexamethasone | Korean Multiple Myeloma Working Party, Celgene Corporation | Multiple Myeloma | | 09/08 | | |
NCT00479167: A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma |
|
|
| Terminated | 2 | 1 | US | Bortezomib and Tositumomab I-131 | Rush University Medical Center, GlaxoSmithKline, Millennium Pharmaceuticals, Inc. | Follicular Lymphoma | 09/08 | 09/08 | | |
| Completed | 2 | 61 | Europe | Bortezomib, Velcade | University Hospital, Toulouse, Intergroupe Francophone du Myelome | Multiple Myeloma | 10/08 | 07/11 | | |
NCT00210327: VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy |
|
|
| Completed | 2 | 33 | Europe | Bortezomib (drug) | International Extranodal Lymphoma Study Group (IELSG) | Lymphoma, Mucosa-Associated Lymphoid Tissue | 11/08 | 04/09 | | |
| Completed | 2 | 72 | Europe | Dexamethasone, Bortezomib, Doxorubicin | Austrian Forum Against Cancer | Multiple Myeloma, Renal Insuficiency | 11/08 | 11/09 | | |
